Philip Mor­ris gets share­hold­er back­ing in Vec­tura saga; Tarve­da strikes ex­clu­sive li­cens­ing agree­ment with Sci­Clone

To­bac­co gi­ant Philip Mor­ris now has crossed the 50% thresh­old it needs for share­hold­er back­ing for its con­tro­ver­sial, $1.5 bil­lion takeover of asth­ma in­haler mak­er Vec­tura.

In­vestors have ac­cept­ed a $2.28-per-share of­fer from the com­pa­ny be­hind Marl­boro cig­a­rettes, ac­cord­ing to Sky News — and those in­vestors rep­re­sent near­ly 75% of the com­pa­ny’s shares.

Ac­quir­ing the British in­haler mak­er is on­ly a part of Philip Mor­ris’ long term plan to de­vel­op “smoke-free” prod­ucts, with a de­sire to ul­ti­mate­ly be­come a “broad­er health­care and well­ness” com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.